Skip to main content
Premium Trial:

Request an Annual Quote

The Magic Pill?

Premium

Three new studies, two in The Lancet and one in Lancet Oncology, say that people who take aspirin every day may have a lower risk of cancer, reports The New York Times' Roni Caryn Rabin. The studies also showed that aspirin may prevent metastasis when taken by cancer patients. Cancer Minute has more on the Lancet Oncology study here.

However, as with most medications, aspirin also has its side effects, and those need to be weighed against the possible benefits before patients decide to start an aspirin regimen, says Nancy Shute at the NPR Shots blog. "Even if it works, that benefit comes with costs, including an increased risk of ulcers and internal bleeding," Shute says, especially as the reduction in cancer risk wasn't really seen in the studies until patients had been taking aspirin daily for at least three years. Two other recent studies — the Women's Health Study and the Physicians' Health Study — did not find a cancer risk benefit to taking aspirin, Shute adds, though that might be because those studies were done on low-dose aspirin.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.